Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-cash Items: 2019-2025

Historic Non-cash Items for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $7.1 million.

  • Beam Therapeutics' Non-cash Items rose 14.97% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year increase of 14.97%. This contributed to the annual value of $5.9 million for FY2024, which is 22.38% up from last year.
  • Per Beam Therapeutics' latest filing, its Non-cash Items stood at $7.1 million for Q3 2025, which was up 4.77% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Non-cash Items registered a high of $300.6 million during Q4 2021, and its lowest value of $1.7 million during Q2 2021.
  • In the last 3 years, Beam Therapeutics' Non-cash Items had a median value of $6.1 million in 2024 and averaged $12.6 million.
  • In the last 5 years, Beam Therapeutics' Non-cash Items skyrocketed by 220.16% in 2021 and then slumped by 96.72% in 2022.
  • Quarterly analysis of 5 years shows Beam Therapeutics' Non-cash Items stood at $300.6 million in 2021, then crashed by 63.07% to $111.0 million in 2022, then crashed by 53.46% to $51.7 million in 2023, then fell by 28.02% to $37.2 million in 2024, then rose by 14.97% to $7.1 million in 2025.
  • Its last three reported values are $7.1 million in Q3 2025, $6.7 million for Q2 2025, and $6.3 million during Q1 2025.